Transplantation of HCV Positive Kidneys Confers Excellent Outcomes for HCV Infected and Uninfected Recipients

J. Torabi, N. Muhdi, A. Montal, J. Melvin, Y. Miura, J. P. Rocca, M. Ajaimy, L. Lirano, Y. Azzi, C. Pynadath, O. Alani, E. Akalin, S. Greenstein, M. Kinkhabwala, J. A. Graham

Montefiore Medical Center, Bronx, NY

Meeting: 2020 American Transplant Congress

Abstract number: A-044

Keywords: Hepatitis C, Kidney transplantation

Session Information

Session Name: Poster Session A: Kidney Deceased Donor Selection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Hepatitis C positive (HCV+) donor kidneys were previously transplanted only into HCV infected recipients (D+/R+). Availability of direct acting anti-virals (DAA) has facilitated the transplantation of an HCV positive kidney into a non-infected patient (D+/R-).

*Methods: Twenty-nine HCV positive patients were transplanted with donor positive kidneys (D+/R+) and 40 HCV negative patients received donor positive kidneys (D+/R-). Post-operatively D+/R- recipients were treated with direct acting anti-virals (DAAs). Center waitlist times and total waitlist allocation days were compared between the two groups. Post-operative outcomes included graft function, acute rejection and graft failure.

*Results: The D+/R- cohort had older recipient (66.9 vs 60.8, p=0.02) and donor age (35.1 vs 29.9, p=0.01) than the D+/R+ group. KDPI was also significantly higher in the D+/R- group (60.9 vs. 44.9, p=0.01).[Table 1] Waitlist times between the D+/R- and D+/R+ groups did not differ significantly in either total allocation time (1340 vs. 1209 days, p=0.61) or center waitlist days (745 vs 543, p=0.28).[Table 1] All D+/R- patients developed HCV viremia post-operatively but achieved SVR with DAA treatment within 12 weeks. Length of stay (5.1 vs 6.1, p=0.33) and incidence of delayed graft function (28 vs 38%, p=0.36) did not differ between D+/R- and D+/R+ groups. Both creatinine and GFR at 1- and 6-months were similar in both groups.[Table 2]. All patient tolerated DAA treatment with no adverse effects from treatment.

*Conclusions: Transplantation of HCV positive kidneys offers excellent outcomes in both HCV positive and negative recipients.

To cite this abstract in AMA style:

Torabi J, Muhdi N, Montal A, Melvin J, Miura Y, Rocca JP, Ajaimy M, Lirano L, Azzi Y, Pynadath C, Alani O, Akalin E, Greenstein S, Kinkhabwala M, Graham JA. Transplantation of HCV Positive Kidneys Confers Excellent Outcomes for HCV Infected and Uninfected Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/transplantation-of-hcv-positive-kidneys-confers-excellent-outcomes-for-hcv-infected-and-uninfected-recipients/. Accessed November 21, 2024.

« Back to 2020 American Transplant Congress